The lifetime risk for a hip fracture in Swedish women and men is 23% and 11%, respectively; dementia doubles this risk, said Prof. Dorota Religa (Karolinska Institutet, Sweden) [1]. Hip fractures are a major cause of morbidity and mortality among the elderly. Dementia is common in this population and complicates recovery from hip fracture surgery, which is the only treatment option. Previous studies have suggested an increased mortality risk in hip fracture patients with dementia, but had several limitations, such as small sample sizes and limited data on dementia subtypes.
To gain insight into the exact association between dementia and mortality after hip fracture surgery, Prof. Religa and colleagues conducted a retrospective cohort analysis including 111,353 Swedish patients aged ≥65 years who underwent hip fracture surgery between 2010 and 2018 [1]. Prof. Religa noted that 22% of the total study cohort had a dementia diagnosis. To examine the impact of dementia subtypes on mortality outcomes, 9 different subtypes were distinguished.
Not surprisingly, mortality rates after hip fracture surgery were higher in the group with dementia: mortality rates were 13% versus 6% (P<0.001) at 30 days post-fracture; 27% versus 12% (P<0.001) at 4 months; and 39% versus 20% (P<0.001) at 1 year. Of the different dementia types, Parkinson’s disease was associated with the highest mortality, especially in the first 4 months after surgery. Prof. Religa added that higher American Society of Anaesthesiologists (ASA) grades, fracture type, poor baseline walking ability, and long-term care residency were also associated with increased mortality.
- Religa D, et al. Mortality after hip fracture surgery in patients with dementia: large Swedish study of over 111 000 patients. OPR-067, EAN Congress 2025, 21-24 June, Helsinki, Finland.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« Lecanemab in AD: not a paradigm shift, but a small step forward Next Article
Why a good result of migraine treatment may not be good enough »
« Lecanemab in AD: not a paradigm shift, but a small step forward Next Article
Why a good result of migraine treatment may not be good enough »
Table of Contents: EAN 2025
Featured articles
Letter from the Editor
Lecanemab in AD: not a paradigm shift, but a small step forward
Neuropathies
Is ChatGPT helpful in diagnosing polyneuropathies?
Riliprubart could be a new treatment option for CIDP
CAR T cell therapy shows promise in severe autoimmune neuropathies
Epilepsy
SUDEP is an underreported cause of death in epilepsy patients
Stroke
Significant impact of implementing thrombectomy in Spanish stroke centres
Sleep
OX2R agonists are a promising causal treatment of narcolepsy
Neurologists must wake up to the importance of sleep
Infectious Diseases
Virus-specific T cells show promise in treating PML
Parkinson's disease
Encouraging results of adaptive DBS for Parkinson’s disease
Cognitive Impairment and Dementia
Dementia doubles the mortality risk 1 year after hip fracture
Lecanemab in AD: not a paradigm shift, but a small step forward
Headache and Migrane
GLP-1R agonists reduce migraine burden in obese patients
Occipital nerve stimulation is no more effective than placebo in cluster headache
Similar efficacy of anti-CGRP mAbs in short- and long-term migraine prevention
Why a good result of migraine treatment may not be good enough
Multiple Sclerosis
Rituximab does not halt progression in non-active secondary progressive MS
Real-world data confirms the effectiveness and safety of ofatumumab in MS
Comparable effectiveness and persistence of ocrelizumab and natalizumab
Muscle/Neuromuscular Disorders
Earlier add-on treatment in myasthenia gravis improves outcomes
Long-term benefits of cipa/mig in late-onset Pompe disease
Related Articles
September 10, 2020
Serum NfL predicts long-term clinical outcomes in MS
July 25, 2024
Therapeutic advancement in spinal muscular atrophy
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
